Source: International Congress 2015 – IPF: clinical aspects
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nadia Hasaneen (Stony Brook, United States of America), Nadia Hasaneen, Tuong Vu, Timothy Fusiak, Hussein Foda, Rany Condos, Gerald Smaldone. Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis. Eur Respir J 2015; 46: Suppl. 59, 2034

Member's Comments

No comment yet.

Related content which might interest you: Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 266s Year: 2005 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Treatment of Idiopathic pulmonary fibrosis with interferon beta - our experience in seven patients Source: Eur Respir J 2003; 22: Suppl. 45, 44s Year: 2003 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Aerosol delivery of an immunomodulator (interferon-γ 1b) within mouse lungs Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Idiopathic pulmonary fibrosis and pirfenidone Source: Eur Respir J 2010; 35: 728-729 Year: 2010 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003